Claudia Zylberberg Appointed as Independent Board Member of POCare Business Subsidiary of Orgenesis
May 30 2023 - 9:30AM
Orgenesis Inc. (NASDAQ: ORGS)
(“Orgenesis” or the “Company”), a global biotech company working to
unlock the full potential of cell and gene therapies (CGTs), today
announced that cell and gene therapy pioneer Claudia Zylberberg,
PhD has been appointed as an independent board member and senior
advisor of its Morgenesis LLC (“Morgenesis”) point-of-care (POCare)
subsidiary. As founder, board member and former CEO of Akron Bio,
Dr. Zylberberg has led Akron Bio to its leadership position among
makers of cGMP-compliant ancillary materials, novel products, and
tools for advanced and regenerative medicines. She is also a member
of the Strategic Advisory Council for the International Society for
Cell & Gene Therapy, sits on the boards for Canada’s CCRM and
the Standards Coordinating Body (SCB) for Regenerative Medicine,
and is co-founder and board chair of ARScience Biotherapeutics, a
clinical developer of immunomodulators.
“We’re very proud to have Claudia join us to
guide Morgenesis as it redefines the possibilities for delivering
POCare therapies,” said Vered Caplan, CEO of Orgenesis. “Her
insights, based on over three decades of experience in the cell
therapy space, will be critical as we assist companies and
hospitals endeavoring to bring cell therapies to more patients,
producing them wherever they are needed.”
“Morgenesis is uniquely situated to bring both
novel technologies, like the Orgenesis Mobile Processing Units and
Labs (‘OMPULs’), and a range of POCare Services in the U.S. and
across the globe,” said Dr. Zylberberg. “Cell and gene therapies
show promise as real, durable cures for a range of challenging
diseases, and I look forward to helping Morgenesis enable potential
life-saving treatments for more patients.”
Earlier this month, Morgenesis secured
additional funding from Metalmark Capital Partners (“Metalmark”),
bringing the total investment from Metalmark to $35 million since
November 2022.
About OrgenesisOrgenesis is a
global biotech company working to unlock the full potential of cell
and gene therapies (CGTs) in an affordable and accessible format at
the point of care. The Orgenesis POCare Platform is comprised of
three enabling components: a pipeline of licensed POCare
Therapeutics that are processed and produced in closed, automated
POCare Technology systems across a collaborative POCare Network.
Orgenesis identifies promising new therapies and leverages its
POCare Platform to provide a rapid, globally harmonized pathway for
these therapies to reach and treat large numbers of patients at
lowered costs through efficient, scalable, and decentralized
production. The POCare Network brings together patients, doctors,
industry partners, research institutes and hospitals worldwide to
achieve harmonized, regulated clinical development and production
of the therapies. www.orgenesis.com.
Notice Regarding Forward-Looking
Statements This press release contains forward-looking
statements which are made pursuant to the safe harbor provisions of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities and Exchange Act of 1934, as amended. These
forward-looking statements involve substantial uncertainties and
risks and are based upon our current expectations, estimates and
projections and reflect our beliefs and assumptions based upon
information available to us at the date of this release. We caution
readers that forward-looking statements are predictions based on
our current expectations about future events. These forward-looking
statements are not guarantees of future performance and are subject
to risks, uncertainties and assumptions that are difficult to
predict. Our actual results, performance or achievements could
differ materially from those expressed or implied by the
forward-looking statements as a result of a number of factors,
including, but not limited to, our reliance on, and our ability to
grow, our point-of-care cell therapy platform and OMPUL business,
our ability to achieve and maintain overall profitability, our
ability to manage our research and development programs that are
based on novel technologies, our ability to control key elements
relating to the development and commercialization of therapeutic
product candidates with third parties, the timing of completion of
clinical trials and studies, the availability of additional data,
outcomes of clinical trials of our product candidates, the
potential uses and benefits of our product candidates, our ability
to manage potential disruptions as a result of the COVID-19
pandemic, the sufficiency of working capital to realize our
business plans and our ability to raise additional capital, the
development of our POCare strategy, our trans differentiation
technology as therapeutic treatment for diabetes, the technology
behind our in-licensed ATMPs not functioning as expected, our
ability to further our CGT development projects, either directly or
through our JV partner agreements, and to fulfill our obligations
under such agreements, our license agreements with other
institutions, our ability to retain key employees, our competitors
developing better or cheaper alternatives to our products, risks
relating to legal proceedings against us and the risks and
uncertainties discussed under the heading "RISK FACTORS" in Item 1A
of our Annual Report on Form 10-K for the fiscal year ended
December 31, 2022, and in our other filings with the Securities and
Exchange Commission. We undertake no obligation to revise or update
any forward-looking statement for any reason.
IR contact for Orgenesis:Crescendo
Communications, LLCTel: 212-671-1021Orgs@crescendo-ir.com
Communications contact for
OrgenesisIB CommunicationsNeil Hunter / Michelle BoxallTel
+44 (0)20 8943
4685neil@ibcomms.agency / michelle@ibcomms.agency
Orgenesis (NASDAQ:ORGS)
Historical Stock Chart
From Apr 2024 to May 2024
Orgenesis (NASDAQ:ORGS)
Historical Stock Chart
From May 2023 to May 2024